美国 · SEC FORM 4
Mineralys Therapeutics, Inc.
MLYS · Nasdaq · CIK 0001933414 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
47 同一窗口内观察到的 Form 4 交易行
24 sales · 23 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-03-30 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. · $1.4M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Rodman David MalcomChief Medical Officer
○▼○▼○▼○▼○▼○▼○▼○▼○▼○▼▼○▼○▼
Warren EricChief Commercial Officer
○▼○▼○▼○▼
Karydas DaphneDirector
○▼○▼
Congleton JonChief Executive Officer
▼▼▼
Slingsby Brian TaylorDirector
▼
Ferguson James J. IIIChief Medical Officer
○
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-30 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M..
近期 Form 4 活动
2买入
76卖出
74其他 Form 4 交易行
52SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出24 sale line(s) · 仅供背景
其他23 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,805,612
- 上期报告
- 9,181,891
- 日均成交量
- 1,513,825
- 回补天数
- 5.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 58,300 | USD 24.16 | USD 1,408,528 | SEC 申报 ↗ |
| 2026-03-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 310,700 | USD 23.67 | USD 7,354,269 | SEC 申报 ↗ |
| 2025-09-04 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 1,176,470 | USD 25.50 | USD 29,999,985 | SEC 申报 ↗ |
| 2025-09-04 | AKKARAJU SRINIVAS | 买入 (P) | Common Stock | 588,235 | USD 25.50 | USD 14,999,992 | SEC 申报 ↗ |
| 2025-03-13 | Catalys Pacific Fund, LP; Slingsby Brian Taylor | 买入 (P) | Common Stock | 259,259 | USD 13.50 | USD 3,499,996 | SEC 申报 ↗ |
| 2025-03-13 | Samsara BioCapital GP, LLC; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 600,000 | USD 13.50 | USD 8,100,000 | SEC 申报 ↗ |
| 2025-03-13 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 1,296,296 | USD 13.50 | USD 17,499,996 | SEC 申报 ↗ |
| 2025-03-13 | AKKARAJU SRINIVAS | 买入 (P) | Common Stock | 600,000 | USD 13.50 | USD 8,100,000 | SEC 申报 ↗ |
| 2024-02-12 | Samsara BioCapital GP, LLC; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 555,555 | USD 13.50 | USD 7,499,992 | SEC 申报 ↗ |
| 2023-11-22 | Congleton Jon | 买入 (P) | Common Stock | 4,250 | USD 5.97 | USD 25,372 | SEC 申报 ↗ |
| 2023-09-06 | Congleton Jon | 买入 (P) | Common Stock | 2,250 | USD 12.08 | USD 27,180 | SEC 申报 ↗ |
| 2023-08-17 | Congleton Jon | 买入 (P) | Common Stock | 2,250 | USD 12.10 | USD 27,225 | SEC 申报 ↗ |
| 2023-08-11 | Congleton Jon | 买入 (P) | Common Stock | 2,000 | USD 12.89 | USD 25,780 | SEC 申报 ↗ |
| 2023-02-14 | Levy Adam Scott | 买入 (P) | Common Stock | 6,250 | USD 16.00 | USD 100,000 | SEC 申报 ↗ |
| 2023-02-14 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 1,250,000 | USD 16.00 | USD 20,000,000 | SEC 申报 ↗ |
Form 4 申报证据
152 transaction lines in the latest 365-day window; 265 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Congleton Jon | 卖出 (S) | Common Stock | 75,000 | USD 25.46 | USD 1,909,665 | SEC 申报 ↗ |
| 2026-09-22 | Slingsby Brian Taylor | 卖出 (S) | Common Stock | 104,320 | USD 28.81 | USD 3,005,459 | SEC 申报 ↗ |
| 2026-09-21 | Warren Eric | 卖出 (S) | Common Stock | 7,438 | USD 28.12 | USD 209,157 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Congleton Jon | 卖出 (S) | Common Stock | 75,000 | USD 25.46 | USD 1,909,665 | SEC 申报 ↗ |
| 2026-09-22 | Slingsby Brian Taylor | 卖出 (S) | Common Stock | 104,320 | USD 28.81 | USD 3,005,459 | SEC 申报 ↗ |
| 2026-09-21 | Warren Eric | 卖出 (S) | Common Stock | 7,438 | USD 28.12 | USD 209,157 | SEC 申报 ↗ |
| 2026-09-21 | Warren Eric | 期权行权／转换 (M) | Common Stock | 7,438 | USD 13.24 | USD 98,479 | SEC 申报 ↗ |
| 2026-09-15 | Karydas Daphne | 卖出 (S) | Common Stock | 3,000 | USD 28.58 | USD 85,740 | SEC 申报 ↗ |
| 2026-09-15 | Karydas Daphne | 期权行权／转换 (M) | Common Stock | 3,000 | USD 12.02 | USD 36,060 | SEC 申报 ↗ |
| 2026-08-21 | Warren Eric | 卖出 (S) | Common Stock | 7,437 | USD 25.98 | USD 193,213 | SEC 申报 ↗ |
| 2026-08-21 | Warren Eric | 期权行权／转换 (M) | Common Stock | 7,437 | USD 13.24 | USD 98,466 | SEC 申报 ↗ |
| 2026-08-10 | Rodman David Malcom | 卖出 (S) | Common Stock | 2,170 | USD 27.09 | USD 58,785 | SEC 申报 ↗ |
| 2026-08-10 | Rodman David Malcom | 期权行权／转换 (M) | Common Stock | 2,170 | USD 16.00 | USD 34,720 | SEC 申报 ↗ |
| 2026-08-10 | Ferguson James J. III | 奖励／授予 (A) | Common Stock | 102,400 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-21 | Warren Eric | 卖出 (S) | Common Stock | 7,438 | USD 26.87 | USD 199,859 | SEC 申报 ↗ |
| 2026-07-21 | Warren Eric | 期权行权／转换 (M) | Common Stock | 7,438 | USD 13.24 | USD 98,479 | SEC 申报 ↗ |
| 2026-07-17 | Rodman David Malcom | 卖出 (S) | Common Stock | 416 | USD 26.53 | USD 11,036 | SEC 申报 ↗ |
| 2026-07-17 | Rodman David Malcom | 期权行权／转换 (M) | Common Stock | 416 | USD 15.44 | USD 6,423 | SEC 申报 ↗ |
| 2026-07-15 | Rodman David Malcom | 卖出 (S) | Common Stock | 6,349 | USD 26.61 | USD 168,947 | SEC 申报 ↗ |
| 2026-07-13 | Rodman David Malcom | 卖出 (S) | Common Stock | 14,058 | USD 27.58 | USD 387,720 | SEC 申报 ↗ |
| 2026-07-13 | Rodman David Malcom | 期权行权／转换 (M) | Common Stock | 14,058 | USD 7.28 | USD 102,365 | SEC 申报 ↗ |
| 2026-07-13 | Congleton Jon | 卖出 (S) | Common Stock | 10,700 | USD 27.24 | USD 291,468 | SEC 申报 ↗ |
| 2026-07-09 | Rodman David Malcom | 卖出 (S) | Common Stock | 2,171 | USD 30.30 | USD 65,781 | SEC 申报 ↗ |
| 2026-07-09 | Rodman David Malcom | 期权行权／转换 (M) | Common Stock | 2,171 | USD 16.00 | USD 34,736 | SEC 申报 ↗ |
| 2026-06-30 | Congleton Jon | 卖出 (S) | Common Stock | 75,000 | USD 26.14 | USD 1,960,460 | SEC 申报 ↗ |
| 2026-06-26 | Warren Eric | 卖出 (S) | Common Stock | 104,124 | USD 25.90 | USD 2,696,812 | SEC 申报 ↗ |
| 2026-06-26 | Warren Eric | 期权行权／转换 (M) | Common Stock | 104,124 | USD 13.24 | USD 1,378,602 | SEC 申报 ↗ |
| 2026-06-17 | Rodman David Malcom | 卖出 (S) | Common Stock | 4,584 | USD 25.00 | USD 114,600 | SEC 申报 ↗ |
| 2026-06-17 | Rodman David Malcom | 期权行权／转换 (M) | Common Stock | 4,584 | USD 14.36 | USD 65,818 | SEC 申报 ↗ |
| 2026-06-17 | Karydas Daphne | 卖出 (S) | Common Stock | 3,000 | USD 25.00 | USD 75,000 | SEC 申报 ↗ |
| 2026-06-17 | Karydas Daphne | 期权行权／转换 (M) | Common Stock | 3,000 | USD 12.02 | USD 36,060 | SEC 申报 ↗ |
| 2026-06-15 | Rodman David Malcom | 卖出 (S) | Common Stock | 9,890 | USD 23.81 | USD 235,481 | SEC 申报 ↗ |
| 2026-06-15 | Rodman David Malcom | 期权行权／转换 (M) | Common Stock | 3,542 | USD 10.20 | USD 36,128 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MLYS |
| CIK | 0001933414 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 265 transaction lines from 2023-02-14 to 2026-09-30 19 P purchase lines · 122 S sale lines · 124 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.